Weight gain during successful tuberculosis treatment increases the risk of post-tuberculosis metabolic syndrome

Clicks: 19
ID: 330784
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #174 of 316 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 316 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Little is known about the relationship between weight gain during treatment and the subsequent risk of cardiovascular and metabolic (cardiometabolic) diseases. We assessed the relationship between changes in body mass index (BMI) during TB treatment with prevalence of post-TB metabolic syndrome, a strong predictor of cardiometabolic diseases. Methods We enrolled a prospective cohort of individuals successfully treated for TB disease in Tbilisi, Georgia, from 2019–2022. Eligible participants were HIV-negative individuals aged ≥16 years with newly diagnosed and laboratory-confirmed pulmonary TB. The primary exposure was relative change in BMI from treatment initiation to treatment completion, dichotomized at ³5% relative increase. Our primary study outcome was prevalence of post-TB metabolic syndrome (≥3 of the following: elevated blood pressure, elevated triglycerides, low high-density lipoprotein, elevated glycated hemoglobin [HbA1c], and abdominal obesity) at any study visits (including the end of, 6- and 12-months post-TB treatment). Multilevel models were used to estimate the effect of BMI change on post-TB metabolic syndrome. Results Among 120 participants, the adjusted risk of having metabolic syndrome after TB treatment among those with ≥5% relative increase in BMI was 2.1 times (95% confidence interval [CI] 1.1–4.0) the risk of those with <5% relative increase in BMI during treatment. Additionally, the adjusted mean of post-TB HbA1c among those with ≥5% relative increase in BMI was 0.4 (95%CI 0.0–0.7) points higher compared to those with <5% relative increase in BMI. Conclusions Among individuals who were successfully treated, individuals who had a ≥5% increase in BMI during TB treatment had a significantly increased risk of metabolic syndrome and higher HbA1c levels up to 12 months after TB treatment.
Reference Key
openalex_W7215058292 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Argita D. Salindri, Teona Avaliani, Mariam Gujabidze, Leila Goginashvili, Sergo A. Vashakidze, Zaza Avaliani, Sara C. Auld, Jeffrey Michael Collins, Jason Randolph Andrews, Russell Ryan Kempker, Hardy Kornfeld, Maia Kipiani, Matthew James Magee
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag620
URL
https://doi.org/10.1093/ofid/ofag620
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.